Celldex Therapeutics Announces Upcoming Presentation at Oppenheimer Healthcare Conference
Celldex Therapeutics Announces Upcoming Presentation at Oppenheimer Healthcare Conference
NEEDHAM, Mass.--(BUSINESS WIRE)-- Celldex Therapeutics, Inc. (NAS: CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present a corporate overview at the Oppenheimer 23rd Annual Healthcare Conference on Wednesday, December 12, 2012 at 10:00 am ET at the Waldorf=Astoria in New York City.
A live webcast of the presentation will be available online on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentation will be available for 30 days following the event.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit www.celldextherapeutics.com.
Celldex Therapeutics, Inc.
Sarah Cavanaugh, 781-433-3161
Vice President of IR & Corp Comm
scavanaugh@celldextherapeutics.com
or
For Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS:
The article Celldex Therapeutics Announces Upcoming Presentation at Oppenheimer Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
